Meta-analysis of a possible signal of increased mortality associated with cefepime use

Clinical Infectious Diseases

Volumn 51, Issue 4, 2010, Pages 381-389

  Kim, Peter W ^a,c   Wu, Yu Te ^b   Cooper, Charles ^b   Rochester, George ^b   Valappil, Thamban ^b   Wang, Yan ^b   Kornegay, Cynthia ^c   Nambiar, Sumathi ^a  

^a Office of Antimicrobial Products   (United States)

^b Office of Biostatistics   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CLINDAMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; MEZLOCILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ABDOMINAL INFECTION; ARTICLE; ATTRIBUTABLE RISK; CAUSE OF DEATH; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; FEBRILE NEUTROPENIA; HUMAN; PNEUMONIA; PRIORITY JOURNAL; SKIN INFECTION; SYSTEMATIC REVIEW; URINARY TRACT INFECTION; ADOLESCENT; ADULT; AGED; BACTERIAL INFECTIONS; CHILD; CLINICAL TRIAL (TOPIC); COMPLICATION; FEMALE; FEVER OF UNKNOWN ORIGIN; INFANT; MALE; META ANALYSIS; MIDDLE AGED; MORTALITY; NEUTROPENIA; NEWBORN; PNEUMONIA, BACTERIAL; PRESCHOOL CHILD; SKIN DISEASES, BACTERIAL; SURVIVAL; URINARY TRACT INFECTIONS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; FEMALE; FEVER OF UNKNOWN ORIGIN; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NEUTROPENIA; PNEUMONIA, BACTERIAL; SKIN DISEASES, BACTERIAL; SURVIVAL ANALYSIS; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 77955682967     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/655131     Document Type: Article

References (27)

1. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-751.
2. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006; 57:176-189.
3. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7:338-348.
4. Sanz MA, López J, Lahuerta JJ, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother 2002; 50:79-88.
5. Lin JC, Yeh KM, Peng MY, Chang F.Y. Efficacy of cefepime versus ceftazidime in the treatment of adult pneumonia. JMicrobiol Immunol Infect 2001; 34:131-137.
6. Kieft H, Hoepelman AI, Rozenberg-Arska M, et al. Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome. Antimicrob Agents Chemother 1994; 38:415-421.
7. Jiang JH,Wang Y. Comparison of the efficacy and safety between cefepime and ceftazidime in the treatment of the moderate to severe low-respiratory tract infection. Chin J Clin Pharmacol Therapeut 2003; 8:92-94.
8. Huang CK, Chen YS, Lee SS, et al. Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections. J Microbiol Immunol Infect 2002; 35:159-167.
9. Chang SC, Fang CT, Hsueh PR, et al. Efficacy and safety of cefepime treatment in Chinese patients with severe bacterial infections: in comparison with ceftazidime treatment. Int J Antimicrob Agents 1998; 10: 245-248.
10. Gentry LO, Rodriguez-Gomez G. Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects. Antimicrob Agents Chemother 1991; 35:2371-2374.
11. Holloway WJ, Palmer D. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections. Am J Med 1996; 100(suppl 6A):52S-59S.
12. Mallet E, Astruc J, Floret D, Kafetzis DA, Nalet V, Gres J.J. Epidemiologic pattern and clinical management of bacterial meningitis in children: a European comparative study of cefepime and cefotaxime. In: Programs and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy.Washington, DC: American Society of Microbiology, 1997. Abstract K-136.
13. Schwartz R, Das-Young LR, Ramirez-Ronda C, Frank E. Current and future management of serious skin and skin-structure infections. Am J Med 1996; 100(suppl 6A):90S-95S.
14. Sharifi R, Geckler R, Childs S. Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections. Am J Med 1996; 100(suppl 6A):76S-82.S.
15. Preheim LC, Childs SJ, Rajfer J, Bittner M.J. Randomized, double-blind comparison of cefepime and ceftazidime therapy for urinary tract infection. Curr Ther Res 1995; 56:729-737.
16. Jehn U, Ruhnke M, Schlimok G, Lew D, Hossfeld K, Huhn D; German- Swiss Cefepime Study Grou.P. Randomized comparison of cefepime/ amikacin versus ceftazidime/amikacin as empiric treatment for febrile neutropenia in cancer patients. Support Care Cancer 1998; 6(suppl): 312.
17. Saito A, Shigeno Y, Irabu Y, et al. A comparative study of cefepime for bacterial pneumonia. Kansenshogaku Zasshi 1992; 66:859-885.
18. Saito A, Shigeno Y, Irabu Y, et al. A comparative study of cefepime for chronic respiratory tract infections. Kansenshogaku Zasshi 1992; 66:886-908.
19. Gainer B, Ho H, Jauregui L, et al. Cefepime (FEP) vs ceftazidime (CAZ) for empiric treatment of sepsis with bacteremia. In: Programs and abstracts of the 35th Interscience Conference on Antimicrobials Agents and Chemotherapy. Washington, DC: American Society of Microbiology, 1995. Abstract LM-22.
20. Greenland S, Robins J.M. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985; 41:55-68.
21. Agresti A. A survey of exact inference for contingency tables. Stat Sci 1992; 7(1):131-153.
22. Chandrasekar PH, Arnow P.M. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. Ann Pharmacother 2000; 34:989-995.
23. Gomez L, Estrada C, Gomez I, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin in the treatment of patients with fever and granulocytopenia. In: Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology, 2001. Abstract L-771.
24. Gomez L, Quintana S, Garau J. Mortality associated with cefepime therapy among neutropenic patients. Clin Infect Dis 2009; 49:987.
25. Towne TG, Lewis JS, Echevarria K. Efficacy and safety of cefepime. Lancet Infect Dis 2009; 9:4-6.
26. Fisher BT, Aplenc R, Localio R, Leckerman KH, Zaoutis T.E. Cefepime and mortality in pediatric acute myelogenous leukemia: a retrospective cohort study. Pediatr Infect Dis J 2009; 28:971-975.
27. Nguyen TD, Williams B, Trang E. Cefepime therapy and all-cause mortality. Clin Infect Dis 2009; 48:902-904.